<http://www.poz.com>

POZ E-mail Update
Tuesday, January 22, 2008


January 21, 2008

Scots Need More Info on HIV
<http://www.poz.com/articles/scotland_hiv_aids_1_13871.shtml>

Ethiopia Plans Widespread Free HIV Treatment by 2010
<http://www.poz.com/articles/ethiopia_hiv_treatment_1_13872.shtml>


January 18, 2008

Tibotec's Intelence (Etravirine, TMC125) is Approved by FDA
<http://www.poz.com/articles/intelence_etravirine_TMC125_761_13870.shtml>
The U.S. Food and Drug Administration announced today that it has
granted approval to Tibotec's Intelence (etravirine), the first new
non-nucleoside reverse transcriptase inhibitor in ten years.

Kaletra Monotherapy Disappoints
<http://www.poz.com/articles/kaletra_monotherapy_hiv_761_13869.shtml>
Contrary to the encouraging findings of several small studies, newly
reported data conclude that Kaletra (lopinavir/ritonavir) monotherapy
is not a durable treatment option for HIV-positive people.

San Franciscos Black MSMs Disproportionately Affected by HIV
<http://www.poz.com/articles/black_msm_hiv_1_13867.shtml>

Latina Sorority Shows Support for HIV Assistance Bill
<http://www.poz.com/articles/hiv_latina_sorority_1_13868.shtml>


January 17, 2008

Low-Dose Interferon Shows Potential for Hep C
<http://www.poz.com/articles/hepatitis_pegintron_pegasys_761_13865.shtml>
A lower dose of PEG-Intron (peginterferon alfa-2b) may be just as
effective against hepatitis C virus (HCV) infection as the standard
dose of PEG-Intron, according to data announced this week by Schering
Plough from their IDEAL study.

Political Turmoil Leaves Displaced HIV-Positive Kenyans Without Meds
<http://www.poz.com/articles/hiv_kenya_meds_1_13861.shtml>

School Attendance May Lower HIV Risk
<http://www.poz.com/articles/hiv_school_risk_1_13862.shtml>

/Rent/ to Close on Broadway This June
<http://www.poz.com/articles/rent_broadway_close_1_13863.shtml>

Washington, DC, Schools to Expand HIV/AIDS Curriculum
<http://www.poz.com/articles/dc_schools_hiv_1_13864.shtml>



Copyright 2008 Smart + Strong, 500 Fifth Avenue, Suite 320, New York,
NY 10110. All rights reserved.